Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a single centre phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9) influenza vaccine in healthy male and female adults, 18 through 49 years of age .
Epistemonikos ID: 58f57fd2f66773f660aa9e10fad1d43113ede7b2
First added on: May 12, 2024